These studies were conducted on mesothelin-positive solid tumors [53, 254], lung cancer [255], glioblastoma [214], esophageal cancer [256], clear cell renal cell carcinoma (ccRCC) [82], and breast cancer [257]. This evidence concerns the gene MSLN and esophageal cancer.